US20080095836A1 - Glutathione-based delivery system - Google Patents
Glutathione-based delivery system Download PDFInfo
- Publication number
- US20080095836A1 US20080095836A1 US12/000,261 US26107A US2008095836A1 US 20080095836 A1 US20080095836 A1 US 20080095836A1 US 26107 A US26107 A US 26107A US 2008095836 A1 US2008095836 A1 US 2008095836A1
- Authority
- US
- United States
- Prior art keywords
- glutathione
- delivery system
- carrier
- active compound
- analgesia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BSNPOBOVFZYPFZ-IIMKOKQASA-N CC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(=O)O.CC(=O)CNC(=O)[C@H](CSC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)NC(=O)CC[C@@H](NC(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1.CC(=O)CNC(=O)[C@H](CSC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)NC(=O)CC[C@H](N)C(=O)O.ClCCl.O=C(CC[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1)N[C@@H](CSC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)O.O=C(O)CC[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1.O=C(O)CNC(=O)[C@H](CSC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)NC(=O)CC[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 Chemical compound CC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(=O)O.CC(=O)CNC(=O)[C@H](CSC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)NC(=O)CC[C@@H](NC(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1.CC(=O)CNC(=O)[C@H](CSC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)NC(=O)CC[C@H](N)C(=O)O.ClCCl.O=C(CC[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1)N[C@@H](CSC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)O.O=C(O)CC[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1.O=C(O)CNC(=O)[C@H](CSC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)NC(=O)CC[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 BSNPOBOVFZYPFZ-IIMKOKQASA-N 0.000 description 1
- 0 [1*]CC.[2*]C([2*])C Chemical compound [1*]CC.[2*]C([2*])C 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Definitions
- the invention relates to a biological delivery system, and more specifically to a glutathione-based delivery system.
- the blood brain barrier is composed of brain endothelial cells capable of blocking foreign substances, such as toxins, due to the tight junctions therebetween. Hydrophobic or low-molecular-weight molecules, however, can pass through the BBB via passive diffusion.
- active compounds such as hydrophilic protein drugs for treating cerebral or nervous diseases and analgesic peptide drugs acting on the central nervous system, cannot enter brain tissue thereby due to large molecular weight or hydrophilicity, resulting in decomposition thereof by enzymes.
- Glutathione is an endogenous antioxidant. If concentration thereof in serum is insufficient, some nervous diseases, such as chronic fatigue syndrome (CFS), may occur.
- CFS chronic fatigue syndrome
- Kiwada Hiroshi provided a liposome capable of accumulation in liver comprising a N-acylglutathione such as N-palmitoylglutathione and a phospholipid such as phosphotidylcholine to target and treat liver diseases recited in JP63002922.
- GSH glutathione
- GSH glutathione
- Zhao Zhiyang provided an anti-cancer pro-drug bonded with glutathione s-transferase (GST)/glutathione (GSH) by sulfonamide covalent bonds to target and treat specific cancer cells after break of the sulfonamide bonds recited in US2003109555.
- This modification can protect amino groups of drugs, increase solubility thereof, and alter absorption and distribution thereof in body.
- opioid-peptide secreted by cerebrum have been separated such as enkephalin, endomorphin-1, and endomorphin-2.
- These natural analgesics, acting on opioid receptors, have lower habituation and respiratory depression than morphine.
- opioid receptors have lower habituation and respiratory depression than morphine.
- such drugs cannot pass through the BBB due to low-stability in plasma. Delivery to the cerebrum can only be accomplished by intracerebroventricular injection or intrathecal injection.
- analgesic peptide drugs is desired preventing decomposition by enzymes and prolonging the analgesic effect thereof.
- the invention provides a delivery system comprising a carrier having a surface an active compound comprising small molecule compounds or peptides for use as an analgesic encapsulated into the carrier, and a glutathione (GSH) or a glutathione derivative grafted on the surface of the carrier.
- a delivery system comprising a carrier having a surface an active compound comprising small molecule compounds or peptides for use as an analgesic encapsulated into the carrier, and a glutathione (GSH) or a glutathione derivative grafted on the surface of the carrier.
- GSH glutathione
- the invention also provides a method of analgesia comprising conducting the active compound to a subject.
- FIG. 1 shows a delivery system of the invention.
- FIG. 2 shows the maximal possible effect (MPE) of various met-enkephalin carriers of the invention.
- FIG. 3 shows the area under curve (AUC) of various met-enkephalin carriers of the invention.
- FIG. 4 shows the maximal possible effect (MPE) of various gabapentin carriers of the invention.
- FIG. 5 shows the area under curve (AUC) of various gabapentin carriers of the invention.
- FIG. 6 shows serum stability of, free met-enkephalin and met-enkephalin in liposomes.
- FIG. 7 shows the maximal possible effect (MPE) of various endomorphin-1 carriers of the invention.
- FIG. 8 shows the licking duration of various endomorphin-1 carriers of the invention.
- FIG. 9 shows the neuropathic pain inhibition of various endomorphin-1 carriers of the invention.
- FIG. 10 shows the pharmacokinetics of various endomorphin-1 carriers of the invention.
- the invention provides a delivery system comprising a carrier having a surface, an active compound comprising small molecule compounds or peptides for use as an analgesic encapsulated into the carrier, and a glutathione (GSH) or a glutathione derivative grafted on the surface of the carrier.
- the carrier may comprise nanoparticle, polymeric nanoparticle, solid liquid nanoparticle, polymeric micelle, liposome, microemulsion, or liquid-based nanoparticle.
- the liposome comprises at least one of lecithin such as soy lecithin and hydrogenated lecithin such as hydrogenated soy lecithin.
- the liposome may further comprise cholesterol, water-soluble vitamin E, or octadecyl amine to increase serum resistance or charge amounts.
- the molar composition ratio of the liposome may be 0.5-100% of lecithin or hydrogenated lecithin, 0.005-775% of cholesterol or water-soluble vitamin E, 0.301-25% of octadecyl amine.
- the carrier has an encapsulation efficiency of about 0.5-100%.
- the active compound may comprise small molecule compounds such as gabapentin, peptides such as enkephalin, proteins, DNA plasmids, oligonucleotides, or gene fragments and have a molar ratio of about 0.0005-50% in the carrier. Some of the small molecule compounds and the peptides may be used as an analgesic.
- the analgesic small molecule compounds may comprise morphine or gabapentin.
- the analgesic peptides may comprise endogenous opioid peptides such as endomorphin-1 or endomorphin-2.
- the targeted carrier may target glutathione transporters of organs such as heart, lung, liver, kidney, or blood brain barrier.
- the active compound can pass through the blood-brain-barrier (BBB), such as brain endothelial cells, with the targeted carrier and has a cell penetration rate of about 0.01-100%.
- BBB blood-brain-barrier
- the invention provides a compound comprising a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene, glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene-glycol derivative.
- a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene, glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene-glycol derivative.
- the vitamin E derivative comprises tocopherol derivatives or tocotrienol derivatives and may be ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocotrienol, ⁇ -tocotrienol, ⁇ -tocotrienol, ⁇ -tocotrienol, ⁇ -tocopherol succinate, ⁇ -tocopherol succinate, ⁇ -tocopherol succinate, ⁇ -tocopherol succinate, ⁇ -tocotrienol succinate, ⁇ -tocotrienol succinate, ⁇ -tocotrienol succinate, ⁇ -tocotrienol succinate, ⁇ -tocotrienol succinate, ⁇ -tocotrienol succinate, ⁇ -tocopherol acetate, ⁇ -tocopherol acetate, ⁇ -tocopherol acetate, ⁇ -tocopherol acetate, ⁇ -tocopherol acetate, ⁇ -
- the phospholipid derivative may have formulae comprising
- a 1 is sphingosine and R 1 may comprise octanoyl or palmitoyl.
- R 1 may comprise octanoyl or palmitoyl.
- a 2 is phosphoethanoamine and R 2 may comprise myristoyl, palmitoyl, stearoyl, or oleoyl.
- the polyethylene glycol (PEG) or the polyethylene glycol derivative has a polymerization number (n) of about 6-210.
- the molecular weight of the polyethylene glycol (PEG) or the polyethylene glycol derivative may be altered with various vitamin E derivatives or phospholipid derivatives. For example, when PEG or its derivative is bonded to vitamin E derivatives, it may have a molecular weight of about 300-10000, when PEG or its derivative is bonded to the phospholipid derivatives represented by formula (I), it may have a molecular weight of about 750-5,000′, and when PEG or its derivative is bonded to the phospholipid derivatives represented by formula (II), it may have a molecular weight of about 350-5,000.
- the polyethylene glycol derivative may comprise carboxylic acid, maleimide, PDP, amide, or biotin.
- the delivery-system 10 comprises a liposome-20 and a ligand-30 grafted thereon.
- the ligand; 30 comprises a moiety 40 comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative 50 bonded thereto, and a glutathione (GSH) or a glutathione derivative 60 bonded to the polyethylene glycol and the polyethylene glycol derivative.
- PEG polyethylene glycol
- GSH glutathione
- Active compounds such as proteins, peptides, or small molecule compounds, transported by the targeted carrier with a novel glutathione (GSH) ligand provided by the invention can effectively pass through blood-brain-barrier by carrier-mediated transcytosis (CMT) or receptor-mediated transcytosis (RMT) to treat cerebral or nervous diseases.
- CMT carrier-mediated transcytosis
- RMT receptor-mediated transcytosis
- the invention also provides a method of analgesia comprising conducting the active compound to a subject.
- the active compound may comprise small molecule compounds or peptides, for use as an analgesic.
- the analgesic small molecule compounds may comprise morphine or gabapentin.
- the analgesic peptides may comprise endogenous opioid peptides such as endomorphin-1 or endomorphin-2.
- the active compound may further be grafted with a glutathione (GSH) or a glutathione derivative, or encapsulated by a carrier grafted with a glutathione (GSH) or a glutathione derivative.
- the carrier may comprise nanoparticle, polymeric nanoparticle, solid liquid nanoparticle, polymeric micelle, liposome, microemulsion, or liquid-based nanoparticle.
- the active compound grafted with the glutathione (GSH) or the glutathione derivative provides longer analgesic effect than the active compound without graft of the glutathione (GSH) or the glutathione derivative thereon.
- the active compound encapsulated by the carrier provides longer analgesic effect than the active compound without encapsulation by the carrier.
- the analgesic peptide drugs such as endomorphin-1 or endomorphin-2 pass through the BBB by, for example, intravenous injection, rather than by intracerebroventricular injection or intrathecal injection. Also, the retention time in plasma of such drugs grafted with glutathione (GSH) or encapsulated by carrier is prolonged, improving analgesic effect.
- GSH glutathione
- N-Cbz Benzyl amino acid N-Cbz Glutamine, 1.0 equiv
- HOSu N-hydroxysuccinimide
- DIC Dicyclohexylcarbodiimide
- the pure compound was obtained in excellent yield (98%) after filtration of the dicyclohexylurea (DCU) formed and evaporation of the solvent. The residue was triturated in Et 2 O/hexanes, filtered out, and then dried in vacuo to afford a white solid.
- DCU dicyclohexylurea
- TPGS-OH d-alpha tocopheryl polyethylene glycol 1000 succinate
- lipid containing 83.2% soybean phosphatidylcholine (SPC), 4.2% ⁇ -tocopherol succinate PEG 1500 (TPGS); 4.2% glutathione-TPGS (GSH-TPGS), and 8.4% cholesterol was placed in a 12.5 mL ZrO 2 mortar.
- Appropriate amounts of met-enkephalin were dissolved in 10 mM phosphate solution with pH7.4 to form a 4% drug solution.
- 0.5 mL drug solution and five ZrO 2 beads (10 mm of diameter) were then added to the mortar and ground with 500 rpm for one hour to form a sticky paste.
- 0.2 g sticky paste and 1.8 mL phosphate solution (10 mM, pH7.4) were added to a 10 mL flask to hydrate under room temperature for one hour to form a carrier solution containing liposomes encapsulating met-enkephalin.
- concentration of met-enkephalin in a liposome was 0.56 mg/mL.
- the encapsulation efficiency thereof was 33.3%.
- the mean diameter of the carrier was 173.1 nm as well as the polydispersity index (PI) was 0.243.
- Example 2-6 Preparation methods of Examples 2-6 are similar to Example 1. The distinctions therebetween are the various carrier compositions, as shown in Tables 1 and 2. TABLE 1 Soy H-soy TPGS- Octadecyl Met- Examples lecithin lecithin Cholesterol TPGS GSH amine enkephalin 2 10 — 1 — 1 — 0.48 3 10 — 1 — 1 1 1.60 4 9 1 1 0.5 0.5 — 1.60 5 9 1 1 0.75 0.25 — 1.60 6 9 1 1 — 1 — 1.60
- lipid containing 83.2% soybean phosphatidylcholine (SPC), 4.2% ⁇ -tocopherol succinate PEG 1500 (TPGS), 4.2% glutathione-TPGS (GSH-TPGS), and 8.4% cholesterol was placed in a 12.5 mL ZrO 2 mortar.
- Appropriate amounts of gabapentin were dissolved in 10 mM phosphate solution with pH7.4 to form a 10% drug solution.
- 0.5 mL drug solution and five ZrO 2 beads (10 mm of diameter) were then added to the mortar and ground with 500 rpm for one hour to form a sticky paste.
- 0.2 g sticky paste and 1.8 mL phosphate solution (10 mM, pH7.4) were added to a 10 mL flask to hydrate under room temperature for one hour to form a carrier solution containing liposomes encapsulating gabapentin.
- concentration of gabapentin in a liposome was 1.08 mg/mL.
- the encapsulation efficiency thereof was 35.7%.
- the mean diameter of the carrier was 147.7 nm as well as the polydispersity index (PI) was 0.157.
- lipid containing 83.2% soybean phosphatidylcholine (SPC), 8.4% ⁇ -tocopherol succinate PEG 1500 (TPGS), and 8.4% cholesterol was placed in a 12.5 mL ZrO 2 mortar.
- Appropriate amounts of met-enkephalin were dissolved in 10 mM phosphate solution with pH7.4 to form a 4% drug solution.
- 0.5 mL drug solution and five ZrO 2 beads (10 mm of diameter) were then added to the mortar and ground at 500 rpm for one hour to form a sticky paste.
- 0.2 g sticky paste and 1.8 mL phosphate solution (10 mM, pH7.4) were added to a 10 mL flask to hydrate under room temperature for one hour to form a carrier solution containing liposomes encapsulating met-enkephalin.
- concentration of met-enkephalin in a liposome was 0.57 mg/mL.
- the encapsulation efficiency thereof was 31.1%.
- the mean-diameter-of the carrier was 164.1 nm as well as the polydispersity index (PI) was 0.281.
- Comparative Examples 2-3 are similar to Comparative Example 1. The distinctions therebetween are the various carrier compositions, as shown in Tables 3 and 4. TABLE 3 Octa- Met- Comparative Soy H-soy Choles- decyl enkeph- Examples lecithin lecithin terol TPGS amine alin 2 10 — 1 1 1 1.60 3 9 1 1 1 — 1.60
- lipid containing 83.2% soybean phosphatidylcholine (SPC), 8.4% ⁇ -tocopherol succinate PEG 1500 (TPGS), and 8.4% cholesterol was placed in a 12.5 mL ZrO 2 mortar.
- Appropriate amounts of gabapentin were dissolved in 10 mM phosphate solution with pH7.4 to form a 10% drug solution.
- 0.5 mL drug solution and five ZrO 2 beads (10 mm of diameter) were then added to the mortar and ground at 500 rpm for one hour to form a sticky paste.
- 0.2 g sticky paste and 1.8 mL phosphate solution (10 mM, pH7.4) were added to a 10 mL flask to hydrate under room temperature for one hour to form a carrier solution containing liposomes encapsilating gabapentin.
- concentration of gabapentin in a liposome was 1.17 mg/mL.
- the encapsulation efficiency thereof was 38.5%.
- the mean diameter of the carrier was 155.8 nm as well as the polydispersity-index (PI) was 0.186.
- Examples 1 and 2 have an apparently higher penetration rate (9.8%) of about 2.82 times greater than comparative example 1 (3.4%).
- Example 3 The penetration rate of met-enkephalin was measured using a RBE4/glioma cell model simulating BBB situations.
- the test results of Example 3 (with glutathione) and Comparative Example 2 (without glutathione) are compared in Table 6.
- Drug dose ⁇ g
- Penetration rate %) SD Comparative 250.0 3.55 0.36
- Example 2 Example 3 250.0 6.99 1.43
- Example 3 250.0 0.25 0.03 (glutathione added)
- Example 3 has an apparently higher penetration rate (6.99%) of about 1.96 times that of Comparative Example 2 (3.55%). Additionally, if cells were cultured with glutathione for 30 min before Example 3 was performed, the penetration rate thereof was lowered by 0.25% due to the addition of glutathione which occupied the glutathione transporter of the cells to block binding of carriers, reducing drug penetration through the BBB. The result proves that the glutathione carrier provided by the invention passes through the BBB via glutathione ligand/transporter binding to induce carrier-mediated transcytosis (CMT) or receptor-mediated transcytosis (RMT).
- CMT carrier-mediated transcytosis
- RTT receptor-mediated transcytosis
- Example 5 After intravenous injection of a drug to a laboratory mouse, the mouse, was put on a 55° C. hot plate to evaluate the analgesic-effect on heat-induced pain.
- the maximal possible effect (MPE) of a 30 mg/mL dose was 13%.
- the maximal possible effect (MPE) of 30 mg/mL dose was 37%.
- Example 5 according to the area under curve (AUC), Example 5 provides 3.2 times the analgesic effect of Comparative Example 3 and 14.7 times the met-enkephalin solution.
- Example 7 provides 1.54 times the analgesic effect of Comparative Example 4 (p ⁇ 0.005) and 2.76 times the gabapentin solution (p ⁇ 0.0005).
- drugs can be safely carried by the carrier with glutathione ligand to pass through the BBB to achieve analgesic effect.
- the 2 carriers provided by Example 5 and fetal bovine serum (FBS) were mixed with 1:1 (v/v) to form a solution. After being placed in a 37° C. water bath for 0, 1, 2, and 4 hours, respectively, the solution was analyzed by gel filtration (Sephrox CL-4B, 75 mm ⁇ 120 mm) and measured residual concentration of met-enkephalin in liposomes. The results are shown in FIG. 6 .
- lipid and 10 mg endomorphin-1 were placed in a 12.5 mL ZrO 2 mortar.
- the molar ratios of soybean phosphatidylcholine (SPC), ⁇ -tocopherol succinate PEG 1000 (TPGS), glutathione-TPGS (GSH-TPGS), and cholesterol in lipid were shown in Tables 7 and 8.
- Phosphate solution with pH7.4, 0.12 mL ethanol, and five ZrO 2 beads (10 mm of diameter) were then added to the mortar and ground with 500 rpm for one hour to form a sticky paste.
- 0.2 g sticky paste and 0.6 mL phosphate solution (10 mM, pH7.4) were added to a 5 mL flask to hydrate under room temperature for one hour to form a liposome encapsulating endomorphin-1.
- the concentration of endomorphin-1 in the liposome was 1.6-1.8 mg/mL.
- Example 17 provides 2 times the analgesic effect of Example 14 and 7 times the endomorphin-1 solution.
- the drug carrier modified by the glutathione ligand can effectively relieve the heat-induced pain.
- the mouse was intravenously injected by a drug to evaluate the analgesic effect on formalin-induced inflammatory pain.
- 1% formalin was injected to the mouse's right thenar.
- the mouse was then intravenously injected by the drug and the licking duration was measured. If the total licking duration was short, the analgesic effect of the drug was good.
- This animal model exhibited an early-phase pain induced by the central nervous system and a late-phase pain induced by the central nervous system and the peripheral nervous system. Suppression of the early-phase pain means that the drug has an analgesic effect on the central nervous system. Referring to FIG.
- Example 17 with glutathione provides 4 times the analgesic effect of Example 14 without glutathione and 7 times the endomorphin-1 solution.
- the sciatic nerve of a male wistar mouse was ligated to build a neuropathic pain animal model. 30 and 120 min after injection of a 2.5 mg/kg dose, the stress forcing the mouse's thenar to shrink was measured to evaluate the analgesic effect on the neuropathic pain. Referring to FIG. 9 , after 30 min, for endomorphin-1 solution, Example 13 and Example 16, no apparent analgesic effect occurred. However, after 120 min, Example 16 with glutathione provides 1.5 times the analgesic effect of Example 13 without glutathione and 9 times the endomorphin-1 solution.
- the plasma concentration of endomorphin-1 of a wistar mouse was analyzed by LC-MS/MS to study the pharmacokinetics of the endomorphin-1 liposome.
- FIG. 10 for 7.5 mg/kg endomorphin-1 solution, no endomorphin-1 was detected merely after 2 hr.
- the endomorphin-1 liposomes of Examples 14 and 17 prolonged the retention time of the endomorphin-1 in plasma to 24 hr.
- T 1/2 was prolonged from 6 min. to 2.4 hr and 1.8 hr, respectively. This result indicates that the stability of the endomorphin-1 in plasma is retained by protection of the liposome.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyethers (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application is a Continuation-In-Part of pending U.S. patent application Ser. No. 11/303,934, filed Dec. 19, 2005, and entitled “GLUTATHIONE-BASED DELIVERY SYSTEM”.
- 1. Field of the Invention
- The invention relates to a biological delivery system, and more specifically to a glutathione-based delivery system.
- 2. Description of the Related Art
- The blood brain barrier (BBB) is composed of brain endothelial cells capable of blocking foreign substances, such as toxins, due to the tight junctions therebetween. Hydrophobic or low-molecular-weight molecules, however, can pass through the BBB via passive diffusion.
- Nevertheless, active compounds, such as hydrophilic protein drugs for treating cerebral or nervous diseases and analgesic peptide drugs acting on the central nervous system, cannot enter brain tissue thereby due to large molecular weight or hydrophilicity, resulting in decomposition thereof by enzymes.
- Current research has developed various methods of allowing active compounds to pass through the BBB, including structural modification to increase hydrophobicity of drugs, absorption-mediated transport (AMT) allowing positive-charged carriers to pass via charge absorption, carrier-mediated transcytosis (CMT) allowing hydrophilic metal ions such as Na+ and K+, di-peptides, tri-peptides or glucose to pass via transporters, and receptor-mediated transcytosis (RMT) allowing macro molecules such as insulin, transferrin, or low-density lipoprotein (LDL) to pass via transcytosis.
- Glutathione (GSH) is an endogenous antioxidant. If concentration thereof in serum is insufficient, some nervous diseases, such as chronic fatigue syndrome (CFS), may occur.
- In 1988, Kiwada Hiroshi provided a liposome capable of accumulation in liver comprising a N-acylglutathione such as N-palmitoylglutathione and a phospholipid such as phosphotidylcholine to target and treat liver diseases recited in JP63002922.
- In 1994, Berislav V. Zlokovic asserted that glutathione (GSH) reaches and passes through the BBB of a guinea pig via a special route, such as GSH-transporter, without decomposition.
- In 1995, Berislav V. Zlokovic asserted that glutathione (GSH) exists in brain, astrocyte and endothelial cells in millimolar concentration.
- In 1995, Ram Kannan asserted that GSH uptake depends on Na+ concentration. If Na+ concentration is low, GSH uptake from brain endothelial cells may be inhibited. Hie also pointed Na-dependent GSH transporter located on the luminal side of the BBB manages GSH uptake and Na-independent GSH transporter located on the luminal side of the BBB manages efflux of GSH. Additionally, Kannan constructed a rat hepatic canalicular GSH transporter (RcGSHT) system using the brains of mice and guinea pigs to analyze
cDNA fragments fragment 7 represents Na-dependent GSH transporter andfragments 5 and 11 represent Na-dependent GSH transporter. - In 1999, Ram Kannan built a mouse brain endothelial cell line (MBEC-4) model simulating BBB situation. The model proved that Na-dependent GSH transporter is located on the luminal side of the MBEC-4 cell.
- In 2000, Ram Kannan asserted that GSH passes through the BBB via Na-dependent GSH transporter in human cerebrovascular endothelial cells (HCBC) and Na-dependent GSH transporter exists in the luminal plasma membrane of HCEC.
- In 2003, Zhao Zhiyang provided an anti-cancer pro-drug bonded with glutathione s-transferase (GST)/glutathione (GSH) by sulfonamide covalent bonds to target and treat specific cancer cells after break of the sulfonamide bonds recited in US2003109555. This modification can protect amino groups of drugs, increase solubility thereof, and alter absorption and distribution thereof in body.
- Additionally, various opioid-peptide secreted by cerebrum have been separated such as enkephalin, endomorphin-1, and endomorphin-2. These natural analgesics, acting on opioid receptors, have lower habituation and respiratory depression than morphine. However, such drugs cannot pass through the BBB due to low-stability in plasma. Delivery to the cerebrum can only be accomplished by intracerebroventricular injection or intrathecal injection.
- Thus, administration of analgesic peptide drugs is desired preventing decomposition by enzymes and prolonging the analgesic effect thereof.
- The invention provides a delivery system comprising a carrier having a surface an active compound comprising small molecule compounds or peptides for use as an analgesic encapsulated into the carrier, and a glutathione (GSH) or a glutathione derivative grafted on the surface of the carrier.
- The invention also provides a method of analgesia comprising conducting the active compound to a subject.
- A detailed description is given in the following embodiments with reference to the accompanying drawings.
- The invention can be more fully understood by reading the subsequent detailed description and examples with references made to the accompanying drawing, wherein:
-
FIG. 1 shows a delivery system of the invention. -
FIG. 2 shows the maximal possible effect (MPE) of various met-enkephalin carriers of the invention. -
FIG. 3 shows the area under curve (AUC) of various met-enkephalin carriers of the invention. -
FIG. 4 shows the maximal possible effect (MPE) of various gabapentin carriers of the invention. -
FIG. 5 shows the area under curve (AUC) of various gabapentin carriers of the invention. -
FIG. 6 shows serum stability of, free met-enkephalin and met-enkephalin in liposomes. -
FIG. 7 shows the maximal possible effect (MPE) of various endomorphin-1 carriers of the invention. -
FIG. 8 shows the licking duration of various endomorphin-1 carriers of the invention. -
FIG. 9 shows the neuropathic pain inhibition of various endomorphin-1 carriers of the invention. -
FIG. 10 shows the pharmacokinetics of various endomorphin-1 carriers of the invention. - The following description is of the best-contemplated mode of carrying out the invention. This description is made for the purpose of illustrating the general principles of the invention and should not be taken in a limiting sense. The scope of the invention is best determined by reference to the appended claims.
- The invention provides a delivery system comprising a carrier having a surface, an active compound comprising small molecule compounds or peptides for use as an analgesic encapsulated into the carrier, and a glutathione (GSH) or a glutathione derivative grafted on the surface of the carrier. The carrier may comprise nanoparticle, polymeric nanoparticle, solid liquid nanoparticle, polymeric micelle, liposome, microemulsion, or liquid-based nanoparticle. The liposome comprises at least one of lecithin such as soy lecithin and hydrogenated lecithin such as hydrogenated soy lecithin.
- The liposome may further comprise cholesterol, water-soluble vitamin E, or octadecyl amine to increase serum resistance or charge amounts. The molar composition ratio of the liposome may be 0.5-100% of lecithin or hydrogenated lecithin, 0.005-775% of cholesterol or water-soluble vitamin E, 0.301-25% of octadecyl amine.
- The carrier has an encapsulation efficiency of about 0.5-100%. The active compound may comprise small molecule compounds such as gabapentin, peptides such as enkephalin, proteins, DNA plasmids, oligonucleotides, or gene fragments and have a molar ratio of about 0.0005-50% in the carrier. Some of the small molecule compounds and the peptides may be used as an analgesic. The analgesic small molecule compounds may comprise morphine or gabapentin. The analgesic peptides may comprise endogenous opioid peptides such as endomorphin-1 or endomorphin-2.
- The targeted carrier may target glutathione transporters of organs such as heart, lung, liver, kidney, or blood brain barrier.
- Specifically, the active compound can pass through the blood-brain-barrier (BBB), such as brain endothelial cells, with the targeted carrier and has a cell penetration rate of about 0.01-100%.
- The invention provides a compound comprising a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene, glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene-glycol derivative.
- The vitamin E derivative comprises tocopherol derivatives or tocotrienol derivatives and may be α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, α-tocotrienol, β-tocotrienol, γ-tocotrienol, δ-tocotrienol, α-tocopherol succinate, β-tocopherol succinate, γ-tocopherol succinate, δ-tocopherol succinate, α-tocotrienol succinate, β-tocotrienol succinate, γ-tocotrienol succinate, δ-tocotrienol succinate, α-tocopherol acetate, β-tocopherol acetate, γ-tocopherol acetate, δ-tocopherol acetate, α-tocotrienol acetate, β-tocotrienol acetate, γ-tocotrienol acetate, δ-tocotrienol acetate, α-tocopherol nicotinate, β-tocopherol nicotinate, γ-tocopherol nicotinate, δ-tocopherol nicotinate, α-tocotrienol nicotinate, β-tocotrienol, nicotinate, γ-tocotrienol nicotinate, δ-tocotrienol nicotiniate, α-tocopherol phosphate, β-tocopherol phosphate, γ-tocopherol phosphate, δ-tocopherol phosphate, α-tocotrienol phosphate, β-tocotrienol phosphate, γ-tocotrienol phosphate, or δ-tocotrienol phosphate.
-
- In formula (I), A1 is sphingosine and R1 may comprise octanoyl or palmitoyl. In formula (II), A2 is phosphoethanoamine and R2 may comprise myristoyl, palmitoyl, stearoyl, or oleoyl.
- The polyethylene glycol (PEG) or the polyethylene glycol derivative has a polymerization number (n) of about 6-210. The molecular weight of the polyethylene glycol (PEG) or the polyethylene glycol derivative may be altered with various vitamin E derivatives or phospholipid derivatives. For example, when PEG or its derivative is bonded to vitamin E derivatives, it may have a molecular weight of about 300-10000, when PEG or its derivative is bonded to the phospholipid derivatives represented by formula (I), it may have a molecular weight of about 750-5,000′, and when PEG or its derivative is bonded to the phospholipid derivatives represented by formula (II), it may have a molecular weight of about 350-5,000.
- The polyethylene glycol derivative may comprise carboxylic acid, maleimide, PDP, amide, or biotin.
- Referring to
FIG. 1 , the delivery system of an embodiment is illustrated. The delivery-system 10 comprises a liposome-20 and a ligand-30 grafted thereon. The ligand; 30 comprises amoiety 40 comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or apolyethylene glycol derivative 50 bonded thereto, and a glutathione (GSH) or aglutathione derivative 60 bonded to the polyethylene glycol and the polyethylene glycol derivative. - Active compounds, such as proteins, peptides, or small molecule compounds, transported by the targeted carrier with a novel glutathione (GSH) ligand provided by the invention can effectively pass through blood-brain-barrier by carrier-mediated transcytosis (CMT) or receptor-mediated transcytosis (RMT) to treat cerebral or nervous diseases.
- The invention also provides a method of analgesia comprising conducting the active compound to a subject.
- The active compound may comprise small molecule compounds or peptides, for use as an analgesic. The analgesic small molecule compounds may comprise morphine or gabapentin. The analgesic peptides may comprise endogenous opioid peptides such as endomorphin-1 or endomorphin-2.
- The active compound may further be grafted with a glutathione (GSH) or a glutathione derivative, or encapsulated by a carrier grafted with a glutathione (GSH) or a glutathione derivative. The carrier may comprise nanoparticle, polymeric nanoparticle, solid liquid nanoparticle, polymeric micelle, liposome, microemulsion, or liquid-based nanoparticle.
- For pain treatment, the active compound grafted with the glutathione (GSH) or the glutathione derivative provides longer analgesic effect than the active compound without graft of the glutathione (GSH) or the glutathione derivative thereon. The active compound encapsulated by the carrier provides longer analgesic effect than the active compound without encapsulation by the carrier.
- In an embodiment, the analgesic peptide drugs such as endomorphin-1 or endomorphin-2 pass through the BBB by, for example, intravenous injection, rather than by intracerebroventricular injection or intrathecal injection. Also, the retention time in plasma of such drugs grafted with glutathione (GSH) or encapsulated by carrier is prolonged, improving analgesic effect.
-
- A stirred solution of N-Cbz Benzyl amino acid (N-Cbz Glutamine, 1.0 equiv) and N-hydroxysuccinimide (HOSu, 1.0 equiv) in 15 mL DME was cooled to 0° C. Dicyclohexylcarbodiimide (DIC, 1.0 equiv) was added and stirred at this temperature for 4 hr. The reaction mixture was allowed to stand for 2 hr in a refrigerator and then filtered.
- As expected, the pure compound was obtained in excellent yield (98%) after filtration of the dicyclohexylurea (DCU) formed and evaporation of the solvent. The residue was triturated in Et2O/hexanes, filtered out, and then dried in vacuo to afford a white solid.
- The (+)-S-tritylcysteine lithium salt (H-Cys(STrt)-OLi, 1.0 equiv) and sodium carbonate (Na2CO3, 5.0 equiv) were dissolved in 15 mL water, and then acetonitrile (CH3CN) was added followed by the intermediated product obtained in Step-2. The mixture was vigorously stirred at room temperature for 3-6 hr until the TLC analysis indicated the absence of intermediated product in Step-2. The solution was washed with water (2*100 mL) and the organic phase was dried with Na2SO4, filtered, and concentrated in vacuo to afford the
compound 2. - A stirred solution of
compound 2 and N-hydroxysuccinimide (HOSu; 1.0 equiv) in 15 mL DME was cooled to 0° C. Dicyclohexylcarbodiimide (DIC, 1.0 equiv) was added and stirred at this temperature for 4 hr. The reaction mixture was allowed to stand for 2 hr in a refrigerator and then filtered. - After the DCU and solvent was removed, the glycine lithium salt (H-Gly-OLi, 1.0 equiv) and sodium carbonate (Na2CO3, 5.0 equiv) were dissolved in 15 mL water, and then acetonitrile (CH3CN) was added followed by the intermediated product obtained in Step-4. The mixture was vigorously stirred at room temperature for 3-6 hr until the TLC analysis indicated the absence of intermediated product in Step-4. The solution was washed with water (2*100 mL) and the organic phase was dried with Na2SO4, filtered, and concentrated in vacuo to afford the
compound 3. - The d-alpha
tocopheryl polyethylene glycol 1000 succinate (TPGS-OH) was coupled withcompound 3 via esterification to affordcompound 4. - The
compound 4 in 100 mL methanol was added 10% Pd—C (0.2 times the weight of protected tripeptide-TPGS). The suspension was stirred at room temperature for 16 hr under a balloon-filled with hydrogen. The suspension was filtered through Celite and evaporated, and the residue was crystallized from ethanol.Compound 5 was obtained. - Triethylsilane (Et3SiH) and TFA-mediated deprotection of
compound 5 in the presence of CH2Cl2 provided the compound 6 (that is GSH-TPGS). - 0.5 g lipid containing 83.2% soybean phosphatidylcholine (SPC), 4.2% α-tocopherol succinate PEG 1500 (TPGS); 4.2% glutathione-TPGS (GSH-TPGS), and 8.4% cholesterol was placed in a 12.5 mL ZrO2 mortar. Appropriate amounts of met-enkephalin were dissolved in 10 mM phosphate solution with pH7.4 to form a 4% drug solution. 0.5 mL drug solution and five ZrO2 beads (10 mm of diameter) were then added to the mortar and ground with 500 rpm for one hour to form a sticky paste. Next, 0.2 g sticky paste and 1.8 mL phosphate solution (10 mM, pH7.4) were added to a 10 mL flask to hydrate under room temperature for one hour to form a carrier solution containing liposomes encapsulating met-enkephalin. The concentration of met-enkephalin in a liposome was 0.56 mg/mL. The encapsulation efficiency thereof was 33.3%. The mean diameter of the carrier was 173.1 nm as well as the polydispersity index (PI) was 0.243.
- Preparation methods of Examples 2-6 are similar to Example 1. The distinctions therebetween are the various carrier compositions, as shown in Tables 1 and 2.
TABLE 1 Soy H-soy TPGS- Octadecyl Met- Examples lecithin lecithin Cholesterol TPGS GSH amine enkephalin 2 10 — 1 — 1 — 0.48 3 10 — 1 — 1 1 1.60 4 9 1 1 0.5 0.5 — 1.60 5 9 1 1 0.75 0.25 — 1.60 6 9 1 1 — 1 — 1.60 -
TABLE 2 Met-enkephalin Mean diameter concentration Encapsulation Examples (nm) PI (mg/mL) efficiency (%) 2 162.7 0.227 0.56 31.70 3 161.4 0.046 4.00 70.33 4 214.1 0.003 3.25 68.85 5 165.3 0.137 3.40 68.48 6 214.5 0.116 3.99 80.78 - 0.5 g lipid containing 83.2% soybean phosphatidylcholine (SPC), 4.2% α-tocopherol succinate PEG 1500 (TPGS), 4.2% glutathione-TPGS (GSH-TPGS), and 8.4% cholesterol was placed in a 12.5 mL ZrO2 mortar. Appropriate amounts of gabapentin were dissolved in 10 mM phosphate solution with pH7.4 to form a 10% drug solution. 0.5 mL drug solution and five ZrO2 beads (10 mm of diameter) were then added to the mortar and ground with 500 rpm for one hour to form a sticky paste. Next, 0.2 g sticky paste and 1.8 mL phosphate solution (10 mM, pH7.4) were added to a 10 mL flask to hydrate under room temperature for one hour to form a carrier solution containing liposomes encapsulating gabapentin. The concentration of gabapentin in a liposome was 1.08 mg/mL. The encapsulation efficiency thereof was 35.7%. The mean diameter of the carrier was 147.7 nm as well as the polydispersity index (PI) was 0.157.
- 0.5 g lipid containing 83.2% soybean phosphatidylcholine (SPC), 8.4% α-tocopherol succinate PEG 1500 (TPGS), and 8.4% cholesterol was placed in a 12.5 mL ZrO2 mortar. Appropriate amounts of met-enkephalin were dissolved in 10 mM phosphate solution with pH7.4 to form a 4% drug solution. 0.5 mL drug solution and five ZrO2 beads (10 mm of diameter) were then added to the mortar and ground at 500 rpm for one hour to form a sticky paste. Next, 0.2 g sticky paste and 1.8 mL phosphate solution (10 mM, pH7.4) were added to a 10 mL flask to hydrate under room temperature for one hour to form a carrier solution containing liposomes encapsulating met-enkephalin. The concentration of met-enkephalin in a liposome was 0.57 mg/mL. The encapsulation efficiency thereof was 31.1%. The mean-diameter-of the carrier was 164.1 nm as well as the polydispersity index (PI) was 0.281.
- Preparation methods of Comparative Examples 2-3 are similar to Comparative Example 1. The distinctions therebetween are the various carrier compositions, as shown in Tables 3 and 4.
TABLE 3 Octa- Met- Comparative Soy H-soy Choles- decyl enkeph- Examples lecithin lecithin terol TPGS amine alin 2 10 — 1 1 1 1.60 3 9 1 1 1 — 1.60 -
TABLE 4 Met-enkephalin Comparative Mean diameter concentration Encapsulation Examples (nm) PI (mg/ml) efficiency (%) 2 159.7 0.103 3.58 70.17 3 149.0 0.168 3.22 69.67 - 0.5 g lipid containing 83.2% soybean phosphatidylcholine (SPC), 8.4% α-tocopherol succinate PEG 1500 (TPGS), and 8.4% cholesterol was placed in a 12.5 mL ZrO2 mortar. Appropriate amounts of gabapentin were dissolved in 10 mM phosphate solution with pH7.4 to form a 10% drug solution. 0.5 mL drug solution and five ZrO2 beads (10 mm of diameter) were then added to the mortar and ground at 500 rpm for one hour to form a sticky paste. Next, 0.2 g sticky paste and 1.8 mL phosphate solution (10 mM, pH7.4) were added to a 10 mL flask to hydrate under room temperature for one hour to form a carrier solution containing liposomes encapsilating gabapentin. The concentration of gabapentin in a liposome was 1.17 mg/mL. The encapsulation efficiency thereof was 38.5%. The mean diameter of the carrier was 155.8 nm as well as the polydispersity-index (PI) was 0.186.
- The penetration rate of met-enkephalin was measured using a RBE4/glioma cell model simulating BBB situations. The test results of Examples 1-2 (with glutathione) and Comparative Example 1 (without glutathione) are compared in Table 5.
TABLE 5 Examples Drug dose (μg) Penetration rate (%) SD Comparative 182.6 3.4 0.6 Example 1 Example 1 167.7 9.8 1.3 Example 2 165.2 9.8 1.2 - The results indicate that Examples 1 and 2 have an apparently higher penetration rate (9.8%) of about 2.82 times greater than comparative example 1 (3.4%).
- The penetration rate of met-enkephalin was measured using a RBE4/glioma cell model simulating BBB situations. The test results of Example 3 (with glutathione) and Comparative Example 2 (without glutathione) are compared in Table 6.
TABLE 6 Examples Drug dose (μg) Penetration rate (%) SD Comparative 250.0 3.55 0.36 Example 2 Example 3 250.0 6.99 1.43 Example 3 250.0 0.25 0.03 (glutathione added) - The results indicate that Example 3 has an apparently higher penetration rate (6.99%) of about 1.96 times that of Comparative Example 2 (3.55%). Additionally, if cells were cultured with glutathione for 30 min before Example 3 was performed, the penetration rate thereof was lowered by 0.25% due to the addition of glutathione which occupied the glutathione transporter of the cells to block binding of carriers, reducing drug penetration through the BBB. The result proves that the glutathione carrier provided by the invention passes through the BBB via glutathione ligand/transporter binding to induce carrier-mediated transcytosis (CMT) or receptor-mediated transcytosis (RMT).
- After intravenous injection of a drug to a laboratory mouse, the mouse, was put on a 55° C. hot plate to evaluate the analgesic-effect on heat-induced pain. Referring to
FIG. 2 , for carriers without glutathione (Comparative Example 3), 90 min after injection, the maximal possible effect (MPE) of a 30 mg/mL dose was 13%. For carriers with glutathione (Example 5), 60 min after injection, the maximal possible effect (MPE) of 30 mg/mL dose was 37%. Referring toFIG. 3 , according to the area under curve (AUC), Example 5 provides 3.2 times the analgesic effect of Comparative Example 3 and 14.7 times the met-enkephalin solution. Thus, drugs can be safely carried by the carrier with glutathione ligand to pass through the BBB to achieve analgesic effect. - After intravenous injection of a drug to a laboratory mouse, the mouse was put on a 55° C. hot plate to evaluate the analgesic effect on heat-induced pain. Referring to
FIG. 4 , for carriers without glutathione (Comparative Example 4), 270 min after injection, the maximal possible effect (MPE) of a 10 mg/mL dose was 3.15%. For carriers with glutathione (Example 7), 180 min after injection, the maximal possible effect (MPE) of a 10 mg/mL dose was 4.47%. Referring toFIG. 5 , according to the area under curve (AUC), Example 7 provides 1.54 times the analgesic effect of Comparative Example 4 (p<0.005) and 2.76 times the gabapentin solution (p<0.0005). Thus, drugs can be safely carried by the carrier with glutathione ligand to pass through the BBB to achieve analgesic effect. - The 2 carriers provided by Example 5 and fetal bovine serum (FBS) were mixed with 1:1 (v/v) to form a solution. After being placed in a 37° C. water bath for 0, 1, 2, and 4 hours, respectively, the solution was analyzed by gel filtration (Sephrox CL-4B, 75 mm×120 mm) and measured residual concentration of met-enkephalin in liposomes. The results are shown in
FIG. 6 . - The results indicate that the concentration of met-enkephalin in liposomes, remains 93% above. However, residual concentration of free met-enkephalin decreases to 2%. It is clear that the carrier provided by the invention has high serum resistance.
- 0.6 g lipid and 10 mg endomorphin-1 were placed in a 12.5 mL ZrO2 mortar. The molar ratios of soybean phosphatidylcholine (SPC), α-tocopherol succinate PEG 1000 (TPGS), glutathione-TPGS (GSH-TPGS), and cholesterol in lipid were shown in Tables 7 and 8. Phosphate solution with pH7.4, 0.12 mL ethanol, and five ZrO2 beads (10 mm of diameter) were then added to the mortar and ground with 500 rpm for one hour to form a sticky paste. Next, 0.2 g sticky paste and 0.6 mL phosphate solution (10 mM, pH7.4) were added to a 5 mL flask to hydrate under room temperature for one hour to form a liposome encapsulating endomorphin-1. The concentration of endomorphin-1 in the liposome was 1.6-1.8 mg/mL.
TABLE 7 Soy H-soy TPGS- Examples lecithin lecithin DPPG Cholesterol Brij 76 TPGS GSH Endomorphin -1 13 10 1 — 1 2 — — 0.32 14 10 1 1 1 2 1 — 0.32 15 10 1 — 1 2 — 0.25 0.32 16 10 1 — 1 2 — 0.5 0.32 17 10 1 1 1 2 0.5 0.5 0.32 -
TABLE 8 Mean Endomorphin-1 Exam- Hydration diameter concentration Encapsulation ples ratio (nm) PI (mg/mL) efficiency (%) 13 1/3 143.7 0.06 1.83 68.06 14 1/3 146.1 0.11 1.66 77.05 15 1/3 147.5 0.03 1.72 62.44 16 1/3 152.3 0.01 1.65 66.31 17 1/3 144.9 0.12 1.97 88.33 - After intravenous injection of a drug to a laboratory mouse, the mouse was put on a 55° C. hot plate to evaluate the analgesic effect on heat-induced pain. Referring to
FIG. 7 , for 7.5 mg/kg endomorphin-1 solution, no analgesic effect occurred. For endomorphin-1 liposomes without glutathione (Example 14), 120 min after injection, the maximal possible effect (MPE) of a 7.5 mg/kg dose was 33%. For endomorphin-1 liposomes with glutathione (Example 17), 60 min after injection, the maximal possible effect (MPE) of a 7.5 mg/kg dose was 57%. Even 5 hours later, Example 17 still remained 30% analgesic effect. The results indicate that more liposomes and endomorphin-1 were taken into brain through the liposomes with GSH ligands capable of targeting the BBB of Example 17. Until the liposomes were collapsed, endomorphin-1 was then slowly released, achieving a long analgesic effect. According to the area under curve (AUC), Example 17 provides 2 times the analgesic effect of Example 14 and 7 times the endomorphin-1 solution. Thus, the drug carrier modified by the glutathione ligand can effectively relieve the heat-induced pain. - After injection of formalin to a laboratory mouse's thenar, the mouse was intravenously injected by a drug to evaluate the analgesic effect on formalin-induced inflammatory pain. 1% formalin was injected to the mouse's right thenar. The mouse was then intravenously injected by the drug and the licking duration was measured. If the total licking duration was short, the analgesic effect of the drug was good. This animal model exhibited an early-phase pain induced by the central nervous system and a late-phase pain induced by the central nervous system and the peripheral nervous system. Suppression of the early-phase pain means that the drug has an analgesic effect on the central nervous system. Referring to
FIG. 8 , for 7.5 mg/kg endomorphin-1 solution, no analgesic effect occurred. The endomorphin-1 liposomes of Examples 14 and 17 shortened the licking duration. Specially, Example 17 with glutathione provides 4 times the analgesic effect of Example 14 without glutathione and 7 times the endomorphin-1 solution. - The sciatic nerve of a male wistar mouse was ligated to build a neuropathic pain animal model. 30 and 120 min after injection of a 2.5 mg/kg dose, the stress forcing the mouse's thenar to shrink was measured to evaluate the analgesic effect on the neuropathic pain. Referring to
FIG. 9 , after 30 min, for endomorphin-1 solution, Example 13 and Example 16, no apparent analgesic effect occurred. However, after 120 min, Example 16 with glutathione provides 1.5 times the analgesic effect of Example 13 without glutathione and 9 times the endomorphin-1 solution. - The plasma concentration of endomorphin-1 of a wistar mouse was analyzed by LC-MS/MS to study the pharmacokinetics of the endomorphin-1 liposome. Referring to
FIG. 10 , for 7.5 mg/kg endomorphin-1 solution, no endomorphin-1 was detected merely after 2 hr. However, the endomorphin-1 liposomes of Examples 14 and 17 prolonged the retention time of the endomorphin-1 in plasma to 24 hr. Also, T1/2 was prolonged from 6 min. to 2.4 hr and 1.8 hr, respectively. This result indicates that the stability of the endomorphin-1 in plasma is retained by protection of the liposome. - While the invention has been described by way of example and in terms of preferred embodiment, it is to be understood that the invention is not limited thereto. To the contrary, it is intended to cover various modifications and similar arrangements (as would be apparent to those skilled in the art). Therefore, the scope of the appended claims should be accorded the broadest interpretation so as to encompass all such modifications and similar arrangements.
Claims (25)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/000,261 US7704956B2 (en) | 2005-12-19 | 2007-12-11 | Glutathione-based delivery system |
US12/244,563 US8067380B2 (en) | 2005-12-19 | 2008-10-02 | Glutathione-based delivery system |
US13/287,480 US8673863B2 (en) | 2005-12-19 | 2011-11-02 | Glutathione-based delivery system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/303,934 US7446096B2 (en) | 2005-12-19 | 2005-12-19 | Glutathione based delivery system |
US12/000,261 US7704956B2 (en) | 2005-12-19 | 2007-12-11 | Glutathione-based delivery system |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/303,934 Continuation-In-Part US7446096B2 (en) | 2005-12-19 | 2005-12-19 | Glutathione based delivery system |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/244,563 Continuation-In-Part US8067380B2 (en) | 2005-12-19 | 2008-10-02 | Glutathione-based delivery system |
Publications (2)
Publication Number | Publication Date |
---|---|
US20080095836A1 true US20080095836A1 (en) | 2008-04-24 |
US7704956B2 US7704956B2 (en) | 2010-04-27 |
Family
ID=36217526
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/303,934 Active 2026-02-16 US7446096B2 (en) | 2005-12-19 | 2005-12-19 | Glutathione based delivery system |
US12/000,261 Expired - Fee Related US7704956B2 (en) | 2005-12-19 | 2007-12-11 | Glutathione-based delivery system |
US12/263,885 Active US7700564B2 (en) | 2005-12-19 | 2008-11-03 | Glutathione based delivery system |
US12/721,633 Active 2027-10-09 US8569239B2 (en) | 2005-12-19 | 2010-03-11 | Glutathione based delivery system |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/303,934 Active 2026-02-16 US7446096B2 (en) | 2005-12-19 | 2005-12-19 | Glutathione based delivery system |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/263,885 Active US7700564B2 (en) | 2005-12-19 | 2008-11-03 | Glutathione based delivery system |
US12/721,633 Active 2027-10-09 US8569239B2 (en) | 2005-12-19 | 2010-03-11 | Glutathione based delivery system |
Country Status (11)
Country | Link |
---|---|
US (4) | US7446096B2 (en) |
EP (2) | EP2837384A1 (en) |
JP (2) | JP4773200B2 (en) |
CN (2) | CN1985804B (en) |
CY (1) | CY1115542T1 (en) |
DK (1) | DK1891962T3 (en) |
ES (1) | ES2516665T3 (en) |
PL (1) | PL1891962T3 (en) |
PT (1) | PT1891962E (en) |
SI (1) | SI1891962T1 (en) |
TW (1) | TWI365754B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015031673A2 (en) | 2013-08-28 | 2015-03-05 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
EP3954393A1 (en) | 2020-08-13 | 2022-02-16 | Bioasis Technologies Inc. | Combination therapies for delivery across the blood brain barrier |
WO2021054927A3 (en) * | 2018-08-10 | 2022-03-03 | South Dakota Board Of Regents | Glutathione-cholesterol derivatives as brain targeting agents |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR549901A0 (en) * | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
US20040057983A1 (en) | 2002-09-25 | 2004-03-25 | David Schmidt | Biomolecular wearable apparatus |
EP1720551B9 (en) * | 2004-03-03 | 2011-09-21 | Vital Health Sciences Pty Ltd. | Alkaloid formulations |
JP5198858B2 (en) * | 2004-08-03 | 2013-05-15 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | Carrier for enteral administration |
US20090239827A1 (en) * | 2005-03-03 | 2009-09-24 | Esra Ogru | Compounds having lipid lowering properties |
EP1893159B1 (en) | 2005-06-17 | 2015-09-30 | Vital Health Sciences Pty Ltd. | A carrier comprising one or more di- and/or monophosphate derivatives of electron transfer agents |
US7446096B2 (en) * | 2005-12-19 | 2008-11-04 | Industrial Technology Research Institute | Glutathione based delivery system |
US8067380B2 (en) * | 2005-12-19 | 2011-11-29 | Industrial Technology Research Institute | Glutathione-based delivery system |
WO2008118013A2 (en) * | 2007-03-23 | 2008-10-02 | To-Bbb Holding B.V. | Targeted intracellular delivery of antiviral agents |
FR2926725B1 (en) * | 2008-01-25 | 2010-09-03 | Biochimie Appliquee Soc | COSMETIC AND / OR DERMATOLOGICAL COMPOSITIONS SCALING |
US8602961B2 (en) * | 2008-05-15 | 2013-12-10 | Lifewave Products Llc | Apparatus and method of stimulating elevation of glutathione levels in a subject |
WO2010061880A1 (en) * | 2008-11-26 | 2010-06-03 | 中外製薬株式会社 | Vesicle preparation |
EP2610343A3 (en) | 2008-11-26 | 2013-09-25 | Chugai Seiyaku Kabushiki Kaisha | Method for designing siRNA and oligoribonucleotides inhibiting HCV |
ES2728225T3 (en) * | 2009-02-20 | 2019-10-23 | 2 Bbb Medicines B V | Glutathione based drug delivery system |
EP2531047A4 (en) | 2010-02-05 | 2014-03-19 | Phosphagenics Ltd | Carrier comprising non-neutralised tocopheryl phosphate |
ES2829386T3 (en) * | 2010-03-30 | 2021-05-31 | Phosphagenics Ltd | Transdermal administration patch |
WO2012122586A1 (en) | 2011-03-15 | 2012-09-20 | Phosphagenics Limited | New composition |
GB201302427D0 (en) | 2013-02-12 | 2013-03-27 | Midatech Ltd | Nanoparticle delivery compositions |
EP3054948B1 (en) | 2013-10-08 | 2020-08-12 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
US10765755B1 (en) * | 2013-11-20 | 2020-09-08 | University Of South Florida | Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies |
FI3125875T3 (en) | 2014-04-04 | 2023-08-24 | Ai Therapeutics Inc | An inhalable rapamycin formulation for treating age-related conditions |
WO2015154897A1 (en) * | 2014-04-08 | 2015-10-15 | Wolfgang Stremmel | Means and methods for treating disorders of copper metabolism |
US20170037184A1 (en) * | 2014-04-17 | 2017-02-09 | The Corporation Of Mercer University | Vitamin e-based nanocarriers for drug delivery and methods of making and using the same |
MX2017004440A (en) | 2014-10-07 | 2017-11-01 | Lam Therapeutics Inc | An inhalable rapamycin formulation for the treatment of pulmonary hypertension. |
US10758520B1 (en) | 2015-05-20 | 2020-09-01 | University Of South Florida | Glutathione-coated nanoparticles for delivery of MKT-077 across the blood-brain barrier |
CN108601732A (en) | 2015-12-09 | 2018-09-28 | 磷肌酸有限公司 | pharmaceutical preparation |
MX2019006845A (en) | 2016-12-21 | 2019-10-15 | Avecho Biotechnology Ltd | Process. |
US10226442B2 (en) * | 2017-07-10 | 2019-03-12 | Syneurx International (Taiwan) Corp. | Lithium salts of N-substituted glycine compounds and uses thereof |
US10842755B2 (en) | 2018-03-23 | 2020-11-24 | University Of South Carolina | Nanoparticles for brain targeted drug delivery |
WO2020242217A1 (en) * | 2019-05-28 | 2020-12-03 | 울산과학기술원 | Liposome comprising glutathione-s-transferase and protein having capacity to bind to target cell or target protein, and use thereof |
TW202228792A (en) | 2020-10-09 | 2022-08-01 | 殷漢生技股份有限公司 | Nanocarrier formulations for inhalation |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5080904A (en) * | 1986-10-28 | 1992-01-14 | Takeda Chemical Industries, Ltd. | Liposome composition and its production |
US5695751A (en) * | 1993-04-08 | 1997-12-09 | Cornell Research Foundation, Inc. | Enhancing delivery of large neutral amino acid drugs |
US20030109555A1 (en) * | 1996-07-03 | 2003-06-12 | Zhiyang Zhao | Targeted drug delivery using sulfonamide derivatives |
US6627732B1 (en) * | 1998-04-16 | 2003-09-30 | Teijin Limited | Glutathione derivatives and their dosage forms |
US7446096B2 (en) * | 2005-12-19 | 2008-11-04 | Industrial Technology Research Institute | Glutathione based delivery system |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60142915A (en) | 1983-12-28 | 1985-07-29 | Lion Corp | Composition for oral cavity |
JPS632922A (en) | 1986-06-20 | 1988-01-07 | Yamanouchi Pharmaceut Co Ltd | Drug carrier |
FR2627385B3 (en) | 1988-02-23 | 1991-08-23 | Serobiologiques Lab Sa | COMPOSITION ESPECIALLY USEFUL AS A BASE MATERIAL FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS, ESPECIALLY DERMATOLOGICAL AND / OR COSMETIC |
JPH0834779A (en) * | 1994-05-20 | 1996-02-06 | Senju Pharmaceut Co Ltd | Tocopherol derivative |
WO1998008490A1 (en) * | 1996-09-01 | 1998-03-05 | Pharmos Corporation | Solid coprecipitates for enhanced bioavailability of lipophilic substances |
WO1998016201A1 (en) * | 1996-10-11 | 1998-04-23 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
US6228347B1 (en) | 1997-12-01 | 2001-05-08 | Thione International, Inc. | Antioxidant gel for gingival conditions |
JP2004323486A (en) * | 2003-04-30 | 2004-11-18 | National Institute Of Advanced Industrial & Technology | Prophylactic and therapeutic eye lotion for retina and/or uvea disease |
CN100515390C (en) * | 2005-04-14 | 2009-07-22 | 蔡海德 | Anterior pituitary adrenocortical extract nano-liposome composite medicine, its preparation method and use |
US8067380B2 (en) * | 2005-12-19 | 2011-11-29 | Industrial Technology Research Institute | Glutathione-based delivery system |
-
2005
- 2005-12-19 US US11/303,934 patent/US7446096B2/en active Active
- 2005-12-27 JP JP2005374896A patent/JP4773200B2/en active Active
- 2005-12-29 ES ES05292820.7T patent/ES2516665T3/en active Active
- 2005-12-29 PT PT52928207T patent/PT1891962E/en unknown
- 2005-12-29 EP EP14180310.6A patent/EP2837384A1/en not_active Ceased
- 2005-12-29 PL PL05292820T patent/PL1891962T3/en unknown
- 2005-12-29 DK DK05292820.7T patent/DK1891962T3/en active
- 2005-12-29 EP EP05292820.7A patent/EP1891962B1/en active Active
- 2005-12-29 SI SI200531880T patent/SI1891962T1/en unknown
- 2005-12-30 TW TW094147661A patent/TWI365754B/en active
-
2006
- 2006-01-19 CN CN200610005869.0A patent/CN1985804B/en active Active
- 2006-01-19 CN CN2008101693581A patent/CN101385859B/en active Active
-
2007
- 2007-12-11 US US12/000,261 patent/US7704956B2/en not_active Expired - Fee Related
-
2008
- 2008-11-03 US US12/263,885 patent/US7700564B2/en active Active
-
2010
- 2010-01-15 JP JP2010007125A patent/JP5394944B2/en active Active
- 2010-03-11 US US12/721,633 patent/US8569239B2/en active Active
-
2014
- 2014-09-10 CY CY20141100728T patent/CY1115542T1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5080904A (en) * | 1986-10-28 | 1992-01-14 | Takeda Chemical Industries, Ltd. | Liposome composition and its production |
US5695751A (en) * | 1993-04-08 | 1997-12-09 | Cornell Research Foundation, Inc. | Enhancing delivery of large neutral amino acid drugs |
US20030109555A1 (en) * | 1996-07-03 | 2003-06-12 | Zhiyang Zhao | Targeted drug delivery using sulfonamide derivatives |
US6653331B2 (en) * | 1996-07-03 | 2003-11-25 | Pharmacia & Upjohn Company | Targeted drug delivery using sulfonamide derivatives |
US6627732B1 (en) * | 1998-04-16 | 2003-09-30 | Teijin Limited | Glutathione derivatives and their dosage forms |
US7446096B2 (en) * | 2005-12-19 | 2008-11-04 | Industrial Technology Research Institute | Glutathione based delivery system |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015031673A2 (en) | 2013-08-28 | 2015-03-05 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
WO2021054927A3 (en) * | 2018-08-10 | 2022-03-03 | South Dakota Board Of Regents | Glutathione-cholesterol derivatives as brain targeting agents |
EP3954393A1 (en) | 2020-08-13 | 2022-02-16 | Bioasis Technologies Inc. | Combination therapies for delivery across the blood brain barrier |
Also Published As
Publication number | Publication date |
---|---|
EP1891962A1 (en) | 2008-02-27 |
US20070141133A1 (en) | 2007-06-21 |
ES2516665T3 (en) | 2014-10-31 |
CN101385859B (en) | 2011-12-07 |
DK1891962T3 (en) | 2014-10-13 |
CN101385859A (en) | 2009-03-18 |
CY1115542T1 (en) | 2017-01-04 |
TWI365754B (en) | 2012-06-11 |
SI1891962T1 (en) | 2014-12-31 |
US7704956B2 (en) | 2010-04-27 |
EP2837384A1 (en) | 2015-02-18 |
PT1891962E (en) | 2014-11-11 |
CN1985804B (en) | 2014-05-14 |
US20090060991A1 (en) | 2009-03-05 |
US20100166849A1 (en) | 2010-07-01 |
JP5394944B2 (en) | 2014-01-22 |
JP2010150264A (en) | 2010-07-08 |
US8569239B2 (en) | 2013-10-29 |
JP2007169252A (en) | 2007-07-05 |
PL1891962T3 (en) | 2015-01-30 |
US7446096B2 (en) | 2008-11-04 |
CN1985804A (en) | 2007-06-27 |
US7700564B2 (en) | 2010-04-20 |
JP4773200B2 (en) | 2011-09-14 |
EP1891962B1 (en) | 2014-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7704956B2 (en) | Glutathione-based delivery system | |
US8673863B2 (en) | Glutathione-based delivery system | |
KR101159477B1 (en) | Abuse resistant amphetamine compounds | |
EP1320386B1 (en) | A novel cationic lipopolymer as biocompatible gene delivery agent | |
JP2000509394A (en) | Polypeptide conjugates for transporting substances across cell membranes | |
JPH09500136A (en) | A self-assembling polynucleotide delivery system containing dendritic polycations | |
Agarwal et al. | Cationic ligand appended nanoconstructs: a prospective strategy for brain targeting | |
CN115040495B (en) | Oral nanometer drug delivery system mediated by small molecule nutrient substances | |
CA2658082A1 (en) | Physiologically active polypeptide- or protein-encapsulating polymer micelles, and method for production of the same | |
US20170326253A1 (en) | Ph-sensitive peptides and their nanoparticles for drug delivery | |
US20100209458A1 (en) | Amphiphilic molecule, molecular assembly comprising the amphiphilic molecule, and use of the molecular assembly | |
WO2020143662A1 (en) | Brain-targeted delivery system for carrier-free nasal nano preparation modified by chitosan oligosaccharide and preparation method therefor | |
Bai et al. | Nanoparticles with surface features of dendritic oligopeptides as potential oral drug delivery systems | |
Krasnov et al. | Nano-sized melphalan and sarcolysine drug delivery systems: synthesis and prospects of application | |
Liu et al. | Amphiphilic endomorphin-1 derivative functions as self-assembling nanomedicine for effective brain delivery | |
KR20180124469A (en) | Nanoliposome for drug delivery to mitochondria containing mitochondria penetrating peptide with conjugated cholesterol in N-terminus as effective component | |
KR20090021065A (en) | Liposome coated with protein to prolong circulation time in bloodstream and preparation method thereof | |
Bodor | Targeting drugs to the brain by sequential metabolism | |
KR100768265B1 (en) | Heparin coated liposomes to prolong circulation time in bloodstream and preparation method thereof | |
Segal et al. | Strategies for peptide delivery to the brain | |
Khare et al. | Amino Acid Coupled Liposomes for the Effective Management of Parkinsonism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE, TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIANG, HSIANG FA;CHEN, YUNG CHU;YANG, TING FAN;AND OTHERS;REEL/FRAME:020282/0826;SIGNING DATES FROM 20071017 TO 20071029 Owner name: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE,TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIANG, HSIANG FA;CHEN, YUNG CHU;YANG, TING FAN;AND OTHERS;SIGNING DATES FROM 20071017 TO 20071029;REEL/FRAME:020282/0826 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552) Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20220427 |